Effects of Hydralazine on Tauromustine in Mice
Author Information
Author(s): M.C. Bibby, P.M. Loadman, A.F. Al-Ghabban, J.A. Double
Primary Institution: University of Bradford
Hypothesis
Does hydralazine enhance the anti-tumour activity of tauromustine by affecting drug pharmacokinetics?
Conclusion
Hydralazine increases the AUC of tauromustine in plasma and tissues, likely contributing to improved anti-tumour effects.
Supporting Evidence
- Hydralazine significantly increased the AUC of tauromustine.
- Plasma clearance of tauromustine decreased after hydralazine treatment.
- Hydralazine reduced the glomerular filtration rate in mice.
Takeaway
When mice were given hydralazine with a cancer drug called tauromustine, the drug stayed in their bodies longer, which might help fight tumors better.
Methodology
Mice were treated with tauromustine and hydralazine, and drug levels were measured in plasma and tissues using HPLC.
Limitations
The study does not address the long-term effects of increased drug exposure on toxicity.
Participant Demographics
Pure strain NMRI mice, 6-8 weeks of age.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website